- Lauren E. Ball, Ph.D.
- Joe B. Blumer, Ph.D.
- Warren Davis Jr., Ph.D.
- Scott Eblen, Ph.D.
- Perry V. Halushka, M.D., Ph.D.
- John D. Hildebrandt, Ph.D.
- Jennifer S. Isaacs, Ph.D.
- Daniel R. Knapp, Ph.D.
- David T. Kurtz, Ph.D.
- Stephen M. Lanier, Ph.D.
- Carola A. Neumann, M.D.
- John E. Oatis, Ph.D.
- Steven A. Rosenzweig, Ph.D.
- Kevin L. Schey, Ph.D.
- Kenneth D. Tew, Ph.D., D.Sc.
- Thomas Walle, Ph.D.
- Michael J. Wargovich, Ph.D.
- Jerry G. Webb, Ph.D.
Kenneth D. Tew, Ph.D., D.Sc.
Professor and Chairman
Cell and Molecular Pharmacology
John C. West Chair of Cancer ResearchProgram Leader - Experimental Therapeutics
Hollings Cancer Center
Ph.D., D.Sc., University of London, Institute of Cancer Research, 1976, 1995
tewk@musc.edu
Tel: 843-792-5062
Fax: 843-792-2475Cancer Drug Development
The development of novel drugs remains a high priority in the successful therapeutic management of cancer. We have applied our accumulated knowledge of glutathione and glutathione S-transferases to the design and testing of new drugs that target glutathione pathways. In collaboration with industrial sector colleagues, a GST activated prodrug is now in late stage clinical testing. In addition, a small molecule peptidomimetic myeloproliferative agent is presently in early clinical testing. We continue to work on the molecular and biochemical mechanisms of these drugs and to elucidate cellular pathways that impact upon drug response and resistance.
Other efforts focus upon the elucidation of the function of a novel human membrane transporter, ABCA2. Continuing studies suggest that cholesterol trafficking may be controlled by this transporter. Its role in human disease states may serve as a prelude to targeting it for therapeutic intervention.
Selected Publications | Additional Publications
Mack J., Beljanski V., Soulika A., Townsend D.M., Brown C.A., Davis W. Jr. and Tew K.D. 'Skittish' ABCA2 knockout mice display tremor, hyperactivity and abnormal myelin ultrastructure in the CNS. Molecular and Cellular Biology 27:44-53, 2007.
Tew K.D. Redox in redux: Emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochemical Pharmacology Commentary 73:1257-1269, 2007.
Townsend D.M., Findlay V.J., Fazilev F., Ogle M., Fraser J., Saavedra J.E., Keefer L.K. and Tew K.D. A glutathione S-transferase pi-activated pro-drug causes kinase activation concurrent with S-glutathionylation of proteins. Molecular Pharmacology 69:501-508, 2006.
Findlay V.J., Townsend D.M., Morris T.E., Fraser J. P. and Tew K.D. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Research 66:6800-6806, 2006.
McIlwain C.C., Townsend D.M. and Tew K.D. Glutathione S-transferase polymorphisms and cancer incidence and therapy. Oncogene 25:1639-1648, 2006.
top of page
